Global X Funds Global X MSCI Vietnam ETF (ARCA: VNAM)

Latest news for Global X Funds Global X MSCI Vietnam ETF (ARCA:VNAM) 

Global X Funds Global X MSCI Vietnam ETF

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Buy and maintains $46 price target.

News

Price Target

Reiteration

Analyst Ratings

KYMR

HC Wainwright & Co. Reiterates Buy on Kymera Therapeutics, Maintains $46 Price Target

Securities Repurchase Program
The Company recently repurchased 641,654 of its common shares in the open market at an average price of&nbsp;$78.26&nbsp;per share under the 2023 Securities Repurchase Program. There is&nbsp;$199.8 million&nbsp;available under the 2023 Securities Repurchase Program as of June 14, 2024.
Second Quarter&nbsp;of 2024 Daily Time Charter Equivalent (&quot;TCE&quot;) Revenues
Below is a summary of the estimated average daily Time Charter Equivalent (&quot;TCE&quot;) revenue and duration of contracted voyages and time charters for the Company&#39;s vessels (both in the pools and outside of the pools) thus far in the&nbsp;second quarter&nbsp;of 2024 as of the date hereof:
<table>
<tbody>
<tr>
<td colspan="3">Pool and Spot Market</td>
<td colspan="4">Time Charters Out of the Pool</td>
</tr>
<tr>
<td colspan="2">Average Daily</td>
<td>Expected</td>
<td colspan="2">% of</td>
<td colspan="2">Average Daily</td>
<td>Expected</td>
<td colspan="2">% of</td>
</tr>
<tr>
<td>Vessel Class</td>
<td colspan="2">TCE Revenue&nbsp;(1)</td>
<td>Revenue Days&nbsp;(2)</td>
<td colspan="2">Days</td>
<td colspan="2">TCE Revenue&nbsp;(1)</td>
<td>Revenue Days&nbsp;(2)</td>
<td colspan="2">Days</td>
</tr>
<tr>
<td>LR2</td>
<td>$</td>
<td>55,000</td>
<td>2,575</td>
<td>81</td>
<td>%</td>
<td>$</td>
<td>30,750</td>
<td>900</td>
<td>100</td>
<td>%</td>
</tr>
<tr>
<td>MR</td>
<td>$</td>
<td>37,000</td>
<td>4,380</td>
<td>88</td>
<td>%</td>
<td>$</td>
<td>21,750</td>
<td>450</td>
<td>100</td>
<td>%</td>
</tr>
<tr>
<td>Handymax</td>
<td>$</td>
<td>28,000</td>
<td>1,225</td>
<td>80</td>
<td>%</td>
<td colspan="2">n/a</td>
<td>n/a</td>
<td colspan="2">n/a</td>
</tr>
</tbody>
</table>

STNG

Scorpio Tankers Updates On Q2 2024 Daily TCE Revenues And Securities Repurchase Program

<ul>
<li>SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed Clinically Meaningful and Nominally Significant Effects in Multiple Key Secondary Efficacy Endpoints</li>
<li>SKYWAY Study in Lennox-Gastaut Syndrome Missed its Primary Endpoint of Reduction in Major Motor Drop Seizures</li>
<li>Soticlestat Showed a Consistent and Favorable Safety and Tolerability Profile in Both Studies</li>
<li>Takeda Will Move Forward to Discuss the Totality of the Data with Regulatory Authorities</li>
</ul>

Biotech

Large Cap

Health Care

General

Takeda Announced Topline Data From SKYLINE And SKYWAY Phase 3 Studies Of Soticlestat (TAK-935) Plus Standard Of Care Versus Placebo Plus Standard Of Care For Refractory Dravet Syndrome, Both The Studies Missed Their Primary Endpoints

AMC Networks expects to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness.

Offerings

AMCX

AMC Networks Intends To Offer $125M Of Convertible Senior Notes Due 2029 In Private Offering

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) with a Buy and maintains $7 price target.

SCLX

HC Wainwright & Co. Reiterates Buy on Scilex Holding, Maintains $7 Price Target

ThinkEquity analyst Ashok Kumar initiates coverage on Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) with a Buy rating and announces Price Target of $4.

Initiation

UMAC

ThinkEquity Initiates Coverage On Unusual Machines with Buy Rating, Announces Price Target of $4

Truist Securities analyst Asthika Goonewardene initiates coverage on Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy rating and announces Price Target of $88.

LEGN

Truist Securities Initiates Coverage On Legend Biotech with Buy Rating, Announces Price Target of $88

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) with a Buy and maintains $12 price target.

INDP

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

B of A Securities analyst Vivek Arya maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy and raises the price target from $150 to $180.

B of A Securities Maintains Buy on ARM Holdings, Raises Price Target to $180

Needham analyst Laura Martin reiterates Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and maintains $700 price target.

NFLX

Needham Reiterates Buy on Netflix, Maintains $700 Price Target

AstraZeneca plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug, Imfinzi (durvalumab), in conjunction with standard chemotherapy, has now <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-the-us-for-endometrial-cancer.html" rel="noreferrer noopener">received </a>endorsement from the U.S. authorities for treating certain severe forms of endometrial cancer.
The U.S. Food and Drug Administration&#8217;s (FDA) approval is specifically for adults with primary, advanced, or recurrent endometrial cancer that shows mismatch repair deficiency (dMMR).
The decision stems from the compelling evidence provided by the DUO-E Phase III trial, which has been documented in the Journal of Clinical Oncology.
In the clinical study, patients treated with Imfinzi in addition to the chemotherapy drugs carboplatin and paclitaxel, followed by a maintenance dose of Imfinzi alone, showed a 58% reduction in the risk of disease progression or death.
This combination demonstrated significant efficacy compared to chemotherapy alone, offering a new beacon of hope for those affected by the challenging condition.
According to Shannon N. Westin, Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center and principal investigator of the trial, &#8220;With the incidence and mortality of endometrial cancer expected to continue to increase significantly in the coming decades, it is more important than ever that we bring new treatment options to patients at the earliest possible moment in their care.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/24/05/39026687/astrazeneca-merck-gsk-struck-record-44-1b-licensing-deals-with-chinese-drugmakers-in-2023-report" rel="noreferrer noopener">AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report</a>
Endometrial cancer, the fourth most prevalent cancer among U.S. women, led to almost 12,000 deaths in 2022.
Despite high survival rates at early stages, advanced cases remain difficult to treat, underscoring the need for effective therapies.
The safety profile of the Imfinzi and chemotherapy regimen aligns well with previous findings, showing manageability and tolerability within expected norms, and continues to be evaluated in ongoing trials including a combination of Imfinzi and Lynparza (olaparib).
AstraZeneca aims to increase its total revenue to $80 billion by 2030, a significant rise from $45.8 billion in 2023, through expansion in its oncology, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">biopharmaceuticals, and rare disease portfolios</a>.
Price Action: AZN shares are down 0.82% at $78.94 during the premarket session at last check Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next: <a href="https://www.benzinga.com/general/biotech/24/05/38924527/pfizer-wins-107-5m-verdict-against-astrazeneca-over-cancer-drug-patent-dispute" target="_blank" rel="noreferrer noopener">Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute</a>
Image by PDPics from Pixabay

Equities

FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer

A coalition of 26 European industry groups has called for a non-discriminatory approach to the proposed European Union Cybersecurity Certification Scheme (EUCS) for cloud services. The groups demanded that tech giants like Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, and Amazon.com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) should not be discriminated against.
What Happened: The European Commission, the EU cybersecurity agency ENISA, and EU member states are set to convene on Tuesday to discuss the EUCS. This scheme is designed to aid governments and businesses in selecting secure and reliable cloud service providers, reported Reuters.
The industry groups, which include the American Chamber of Commerce to the EU and the European Payment Institutions Federation, have expressed concerns that the EUCS might unfairly target major U.S. tech companies.
&#8220;We believe that an inclusive and non-discriminatory EUCS that supports the free movement of cloud services in Europe will help our members prosper at home and abroad, contribute to Europe&#8217;s digital ambitions, and strengthen its resilience and security,&#8221; the groups said in a joint letter to EU countries.
The proposed EUCS, which has been under review since 2020, has undergone several changes. A recent version eliminated the sovereignty requirements, which previously mandated U.S. tech giants to establish a joint venture or collaborate with an EU-based company to store and process customer data within the EU to qualify for the highest level of the EU cybersecurity label.
See Also: <a href="https://www.benzinga.com/news/24/06/39349293/microsoft-regional-chief-says-this-country-has-caught-up-in-ai-technology-and-continues-to-pick-up-t?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Microsoft Regional Chief Says This Country Has &#8216;Caught Up&#8217; In AI Technology And Continues To Pick Up The Pace</a>
The industry groups have emphasized the importance of an inclusive and non-discriminatory EUCS to support the free movement of cloud services in Europe, contributing to Europe&#8217;s digital ambitions and strengthening its resilience and security.
Why It Matters: The proposed EUCS has been a topic of contention in the tech industry. The removal of sovereignty requirements was a significant shift from the previous proposal, which had mandated U.S. tech giants to collaborate with EU-based companies to store and process customer data in the EU.
This development comes in the wake of increasing <a href="https://www.benzinga.com/government/24/06/39312639/microsoft-under-fire-president-brad-smith-to-testify-on-security-lapses-after-major-cyberattacks">cybersecurity concerns</a> globally, with major tech companies being at the forefront of these discussions. For instance, Microsoft faced criticism for its <a href="https://www.benzinga.com/news/24/04/38190146/microsofts-latest-security-breach-whats-at-stake-for-company-integrity-and-trust">security lapse</a> earlier this year and is now under scrutiny for its security measures after breaches by Russian and Chinese hackers.
Meanwhile, companies like CrowdStrike are taking proactive measures to <a href="https://www.benzinga.com/markets/equities/24/03/37811329/weve-got-the-data-theyve-got-the-power-crowdstrike-ceo-on-nvidia-collaboration-and-ai-for-cybers">enhance their cybersecurity capabilities</a>, with collaborations like the one with NVIDIA Corp to leverage advanced AI technology.
Read Next: <a href="https://www.benzinga.com/news/24/06/39265691/a-day-after-shutting-down-tesla-phone-rumors-elon-musk-says-it-is-not-out-of-the-question?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">A Day After Shutting Down Tesla Phone Rumors, Elon Musk Says It Is &#8216;Not Out Of The Question&#8217;</a>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Global

Tech

AMZN

GOOG

GOOGL

MSFT

Microsoft, Google, And Amazon Should Not Be Discriminated Against, EU Groups Demand As They Rally For 'Inclusive' Cybersecurity Label

Baird analyst Colin Sebastian maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Outperform and raises the price target from $57 to $58.

EBAY

Baird Maintains Outperform on eBay, Raises Price Target to $58

HC Wainwright &amp; Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Buy and maintains $19 price target.

COGT

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $19 Price Target

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $41 price target.

SNDX

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target

Ennis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBF#NYSE">EBF</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.36 by 13.89 percent. This is a 8.89 percent decrease over earnings of $0.45 per share from the same period last year. The company reported quarterly sales of $103.11 million which beat the analyst consensus estimate of $100.85 million by 2.24 percent. This is a 7.36 percent decrease over sales of $111.29 million the same period last year.

Earnings

Ennis Q1 EPS $0.41 Beats $0.36 Estimate, Sales $103.11M Beat $100.85M Estimate

Bloomberg ETF analyst Eric Balchunas moved up the launch date for the <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39315645/gary-gensler-ethereum-spot-etfs-could-start-trading-by-the-end-of-summer">highly anticipated spot Ether ETF</a> to July 2. 
What Happened: This adjustment comes after the SEC staff sent light comments on the S-1 filings to issuers, asking for revisions within a week.
&#8220;Decent chance they work to declare them effective the next week and get it off their plate before the holiday weekend. Anything is possible but this is our best guess as of now,&#8221; Balchunas <a href="https://x.com/EricBalchunas/status/1801725292404261308">tweeted</a>.
Issuers had been awaiting comments from the SEC&#8217;s Corporation Finance (Corp Fin) division, which received the S-1 filings two weeks prior. 
<a href="https://x.com/EricBalchunas/status/1801297811067031946">According</a> to Balchunas, Corp Fin only recently began reviewing these documents due to a last-minute shift in priorities, likely driven by political factors.
SEC Chair Gary Gensler previously indicated that approvals could come &#8220;over the course of this summer,&#8221; while Senator Bill Hagerty suggested they would be finalized &#8220;by the end of the summer.&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39338345/bitcoin-plunges-below-66k-these-indicators-show-if-its-time-to-use-the-escape-hatch#google_vignette">Bitcoin Plunges Below $66K: These Indicators Show If It&#8217;s Time To Use The Escape Hatch</a>
Recent Market Movements And Sentiment
In parallel, the digital asset market has been experiencing significant movements. 
<a href="https://blog.coinshares.com/volume-187-digital-asset-fund-flows-weekly-report-03a835f3e795">According </a>to CoinShares, the market saw outflows totaling $600 million, the largest since March 22, 2024. 
The outflows were primarily driven by a hawkish Federal Open Market Committee (FOMC) meeting, which prompted investors to reduce exposure to fixed-supply assets like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>). 
Bitcoin alone saw outflows of $621 million, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), LIDO (CRYPTO: LIDO), and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) received inflows of $13 million, $2 million, and $1 million respectively.
Regionally, the United States experienced the bulk of the outflows, totaling $565 million. 
Other regions like Canada, Switzerland, and Sweden also saw negative sentiment, with outflows of $15 million, $24 million, and $15 million respectively. 
Germany bucked the trend with inflows of $17 million.
The bearish sentiment towards Bitcoin also led to $1.8 million in inflows into short-Bitcoin products.
Future Implications
The adjustment in the Ether ETF launch date could provide a new catalyst for market dynamics, potentially influencing investor behavior and market sentiment. 
The anticipation around the launch highlights the increasing integration of digital assets into mainstream financial products and the evolving regulatory landscape.
For those looking to gain deeper insights into these developments and the future of digital assets, Benzinga&#8217;s<a href="https://www.benzinga.com/events/digital-assets/agenda/"> Future of Digital Assets </a>event on Nov. 19 will be a key platform.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39337183/paul-ryan-urges-america-to-embrace-stablecoins-to-maintain-dollar-dominance">Paul Ryan Urges America To Embrace Stablecoins To Maintain Dollar Dominance</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Spot Ethereum ETF Launch Date Possibly On July 2: Bloomberg Analyst

Morgan Stanley analyst Bob Huang initiates coverage on Bowhead Specialty Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOW#NYSE">BOW</a>) with a Equal-Weight rating and announces Price Target of $26.

Morgan Stanley Initiates Coverage On Bowhead Specialty Holding with Equal-Weight Rating, Announces Price Target of $26

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) with a Buy and maintains $4 price target.

BITF

HC Wainwright & Co. Reiterates Buy on Bitfarms, Maintains $4 Price Target

B of A Securities analyst Derek Hewett initiates coverage on Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) with a Buy rating and announces Price Target of $17.5.

KBDC

B of A Securities Initiates Coverage On Kayne Anderson BDC with Buy Rating, Announces Price Target of $17.5

APAC Manufacturing Sector Rebounds In Late 2023

Global X MSCI Vietnam ETF declares semi-annual distribution of $0.0517

APAC Economic Outlook For 2024 Remains Bright

VNM: Still An Attractive Frontier Market Growth Story

Investing Themes For 2024

ASEAN Economic Outlook In 2024

Redefining Risk - Geopolitical Insights For 2024

Asia-Pacific Is Not Just China

How Does Global 'Friend-Shoring' Affect Chinese Manufacturers?

VNM: The Go-To Vehicle To Capture Vietnam's Upside

AAXJ

ACTV

ADIV

AFMC

AFSM

AFTY

AGNG

ANEW

ARKG

ARKK

ARKQ

ARKW

ASEA

ASHR

ASHS

ASHX

AVUV

BAPR

BBAX

BBJP

BMED

BOTZ

BRZU

BTEC

CBON

CHIC

CHIE

CHIH

CHII

CHIK

CHIM

CHIQ

CHIR

CHIS

CHIU

CHIX

CIBR

CNCR

CNXT

CNYA

CQQQ

CXSE

DBJP

DTEC

DVYA

DXJS

ECNS

EDOC

EEMA

EGPT

EIDO

EPHE

EPOL

EWJV

EWZS

FHLC

FINX

FITE

FLAU

FLAX

FLBR

FLCH

FLHK

FLIN

FLJH

FLJP

FLKR

FLMX

FLSA

FLTW

FTEC

FTXH

FTXL

GAMR

GERM

GLIN

GNOM

GSJY

HACK

HART

HAUZ

HELX

HEWJ

HTEC

IBBQ

IDGT

IDNA

IGPT

INCO

INDA

INDF

INDL

INDY

IPAC

IRBO

ISRA

ITEQ

IVOO

IVOV

JPXN

KALL

KBND

KBUY

KEJI

KFVG

KGRN

KNCT

KOMP

KORU

KSTR

KTEC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

News

Latest news for Global X Funds Global X MSCI Vietnam ETF (ARCA:VNAM)

Wednesday, September 28, 2022